Prof Shahneen Sandhu
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
473 Scholarly works
9 Projects
HIGHLIGHTS
2026
Journal article
MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition.
DOI: 10.1158/1078-0432.CCR-25-39512026
Journal article
Convergent evolution of complex structural variants drives therapy resistance in metastatic prostate cancer.
DOI: 10.1186/s13059-026-04074-22026
Journal article
Radiographic Progression Without Prostate-specific Antigen Progression in Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Analysis of the ENZAMET Trial (ANZUP 1304)
DOI: 10.1016/j.euo.2026.01.0082019
Research Grant
Up-Front Psma Alliance: Using Theranostics Early to Eradicate Prostate Cancer and Developing Novel Startegies for Psma-Negative Disease
2017
Conference Proceedings
Lutetium-177 PSMA (LuPSMA) theranostics phase II trial: Efficacy, safety and QoL in patients with castrate-resistant prostate cancer treated with LuPSMA
DOI: 10.1093/annonc/mdx370.0022017
Research grants (other domestic)
Novel Approaches for Overcoming Resistance to Therapies for Advanced Melanoma
2017
Research Grant
Combination of Radionuclide 177lu-Psma Therapy With Pembrolizumab in Patients With Metastatic Castration-Resistant Prostate Cancer (Mcrpc)
RECENT SCHOLARLY WORKS
2026
Journal article
[177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study
DOI: 10.1016/S1470-2045(26)00017-32026
Journal article
Niraparib With Abiraterone Acetate Plus Prednisone as First-Line Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Repair Gene Alterations: Final Analysis of the Asian Subgroup From the MAGNITUDE Study
DOI: 10.1111/iju.704552026
Journal article
177Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate Cancer
DOI: 10.1148/radiol.2526722026
Journal article
Tumors located in the brain impair the frequency and phenotype of dendritic cells in blood and tumor
DOI: 10.1016/j.isci.2026.1151602026
Journal article
Immune checkpoint inhibitor-associated myocarditis: A novel risk score
DOI: 10.1093/eurheartj/ehaf3152026
Journal article
The diversity and clinical relevance of germline DNA damage repair gene variants in 3005 patients with metastatic prostate cancer.
DOI: 10.1200/jco.2026.44.7_suppl.2272026
Journal article
Safety and efficacy of pasritamig (PAS) docetaxel (DOCE) in participants with metastatic castration-resistant prostate cancer (mcrPc): Initial results of a phase 1b study.
DOI: 10.1200/jco.2026.44.7_suppl.171
RECENT PROJECTS
2021
Research grants (international)
Identifying Genetic, Transcriptional and Microenvironment Drivers of Lethal Prostate Cancer for Better Patient Stratification, Disease Tracking and Drug Target Discovery